Leading Precision Medicine In South East Asia (SEA)

Pathomics Health focuses on advanced precision medicine diagnostics and digital healthcare solutions to provide patients access to better outcome.

EarlyCDT-Lung

The EarlyCDT ® Lung is a CE-IVD and HSA-approved diagnostic test that uses a blood sample to detect a panel of seven lung cancer autoantibodies in humans. The test aids in the early detection of lung cancer in high-risk individuals and in the assessment of risk in patients with indeterminate pulmonary nodules identified through CT scans.

LEARN MORE

DNlite-DKD

The DNlite-DKD test is an in-vitro diagnostic test approved by the Health Sciences Authority (HSA). It is designed to assist clinicians in assessing the risk of kidney function decline in individuals with Type 2 diabetes who show signs of albuminuria (protein in the urine). The test is used alongside clinical evaluations for a more comprehensive prognosis.

LEARN MORE

Leading Precision Medicine In South East Asia (Sea)

Pathomics Health focuses on advanced precision medicine diagnostics and digital healthcare solutions to provide patients access to better outcome.

Our Mission

Advancing Diagnostics & Digital Health Solutions for Better Health

We focus on advanced precision medicine diagnostics and digital healthcare solutions.

Our Vision

Universal Accessibility to Affordable Precision Diagnostics & Screening

We offer an innovative, scalable and cost-effective advanced diagnostics platform, combining with cutting-edge technology and design to help patients and individuals to improve their health.

Our Commitment

We are committed in delivering high-quality and yet affordable diagnostics solutions to meet the diverse needs of our customers. Contact us today to find out more about our service offerings.

Company Milestones - Driving Excellence Since 2017

Our Laboratories

Investor Relations

Pathomics Health takes a proactive approach in managing its Investor Relations to cultivate strong relationships and effective communication with its investors. This involves regular engagement with stakeholders to foster trust and provide timely updates on financial performance, market conditions, and strategic initiatives. Through transparent and consistent communication, the company aims to enhance investor understanding, confidence, and engagement.
VIEW FILE